Beyond the Straight Line: Rethinking How We Forecast Clinical Trial Timelines

For decades, clinical trials have relied on a deceptively simple construct to forecast study duration: a fixed enrollment rate resulting in near straight-line projections. This metric has anchored feasibility assessments, operational plans, investor communications and executive dashboards. Yet across thousands of global trials, one truth persists: this projection is invariably wrong.

Enrollment in clinical research is not linear. It is dynamic, regionally variable, seasonally affected, operationally constrained and behaviorally driven. However, the industry continues to communicate timelines as though patient accrual follows a predictable, constant slope.

The industry is now equipped with the computational and analytical capabilities needed to evolve. Advances in machine learning (ML) and neural networks enable uptake of real-time signals and generate non-linear reforecasts that better approximate reality.

The time has come to move beyond fixed enrollment rates as the defining metric of clinical trial timelines and instead begin communicating in milestone projections driven by dynamic, continuous learning models. This transition will require thoughtful change management, transparency and hybrid approaches. The opportunity to improve predictability, credibility and execution discipline is significant.

The straight-line trajectory is a fallacy

Traditional forecasting models rely on several simplifying assumptions, including a consistent enrollment rate per site, predictable site activation timelines, stable patient availability and static operational conditions.

These assumptions produce a linear projection from first patient in (FPI) to last patient in (LPI). In practice, however, enrollment trajectories rarely follow this pattern.

Observed deviations are not anecdotal but systemic. For example:

• Global Phase III studies frequently see early overperformance followed by mid-study slowdowns, driven by site fatigue and patient pool depletion.
• Regulatory delays or protocol amendments may shift enrollment trajectories by months within a single quarter.
• Competitive trial launches in overlapping indications often reduce screening rates by double-digit percentages in affected regions.

Even models that assume curved enrollment (e.g., sigmoid patterns) fail to capture the variability and discontinuities observed in real-world execution. The implication is not that forecasting is impossible but that static models systematically underrepresent uncertainty and delay visibility into trajectory changes.

The persistence of fixed-rate forecasting is understandable. It provides simplicity in planning and communication, a common language across sponsors, CROs and sites and compatibility with financial models and reporting structures.

However, these benefits come at a cost. When projections diverge, organizations rely on reactive mitigation strategies such as adding sites or expanding geographies, typically after meaningful delays. In effect, the industry has optimized for general purpose and simplicity rather than predictive accuracy.

Machine learning offers an opportunity

Modern ML approaches offer an alternative by incorporating diverse, time-dependent inputs, such as:

• Site-level performance trends.
• Screening-to-enrollment conversion rates.
• Activation delays and startup variability.
• Competitive trial activity.
• Regional and epidemiological signals.
• Operational lag indicators.

Rather than assuming a fixed trajectory, these models continuously update projections as new data becomes available. This enables ongoing recalibration of milestone timelines, earlier identification of inflection points, region-specific forecasting adjustments and scenario-based planning under different assumptions.

It is important to acknowledge limitations. ML models are only as reliable as the data that informs them. Incomplete, biased or delayed data may reduce forecast quality. Additionally, model governance, transparency and validation processes are critical to ensuring outputs are interpretable and defensible.

When implemented with these considerations, dynamic forecasting does not eliminate uncertainty. However, it does provide a more responsive and evidence-based representation of it.

Known barriers to adoption

Despite its promise, ML-driven timeline projection faces meaningful resistance. Two prominent barriers that continually surface include the black box concern and change management complexity.

In clinical research, decision-making has long been grounded in principles that prioritize transparency, whether through the scientific method, biostatistics or clearly defined mechanisms of action. These frameworks do more than generate answers; they provide a rationale that may be interrogated, validated and trusted. By contrast, many advanced ML models have historically offered limited visibility into how specific inputs translate into projected outcomes. This perceived black box dynamic creates a fundamental tension. While the outputs may be directionally compelling, the absence of clear interpretability erodes confidence among stakeholders diminishing adoption.

Specifically, study teams may ask:

• Why did the model change the LPI forecast?
• Which variables influenced the shift?
• How do we defend this projection internally?

Transparency and explainability must accompany implementation. Interpretable ML frameworks and feature attribution tools provide visibility into key drivers reassuring study teams while providing supportive narratives in stakeholder communications.

Further, project managers have been trained to think in terms of enrollment rates. CRO contracts, feasibility assessments and executive reviews revolve around this metric. This shift requires re-education and cultural adjustment.

However, the industry has already embraced advanced analytics in safety monitoring, risk-based quality management and centralized monitoring. The operational shift for timeline forecasting is comparatively modest and non-regulatory in nature.

A staged approach offers a pragmatic transition strategy

Transitioning away from fixed-rate forecasting does not require abrupt replacement. A staged approach may preserve familiarity while introducing more adaptive methods such as dual reporting, segmented enrollment rates and continuous validation.

Dual reporting enables sponsors to maintain traditional enrollment rate projections alongside dynamic milestone forecasts. This allows for direct comparison and builds organizational confidence in model outputs over time.

Segmented (“pseudo”) enrollment rates translate dynamic projections into time-bound segments (e.g., months 0–3, 4–6, 7–12). This retains a rate-based structure while reflecting changing performance across the study lifecycle.

Continuous validation of dynamic models should be evaluated through:

• Ongoing measurement of forecast accuracy.
• Regular recalibration as new data is incorporated.
• Reporting of confidence intervals and probability ranges.
• Clear articulation of key drivers influencing projections.

Positioning forecast outputs as probabilistic (LPI has an 80% probability of occurring within this 60-day window) rather than deterministic (LPI is projected on this exact date) aligns expectations with real-world variability.

An opportunity for change

The clinical trial ecosystem is primed to move beyond enrollment rates as artificial intelligence (AI) becomes embedded in clinical workflows. Machine learning infrastructure, real-time data streams, and computational power exist. What remains is leadership. The opportunity exists for sponsors to drive this transition, in partnership with CROs, partners/vendors, as well as internally. Sponsors should:

• Request ML-overlay projections during feasibility, planning, and execution.
• Incentivize forecast accuracy over enrollment rate adherence.
• Shift project timeline oversight towards milestone probability windows.
• Invest in explainable AI frameworks for operational planning.

The industry does not lack data, tools or computational intelligence. An opportunity for change lies in the collective will to modernize how we define and communicate timelines. The time has come for the clinical research industry to innovate and embrace the use of advanced ML in forecasting clinical research timelines.

Clinical trial enrollment is non-linear, dynamic and influenced by multivariate forces that defy straight-line projections. Continuing to anchor timeline communication to fixed enrollment rates reflects entrenched business habits rather than computational constraint.

ML offers a path forward toward continuous learning and dynamically recalibrated milestone forecasting. Like digital twins in advanced engineering sectors, these models mirror live performance and adapt in real time.

The transition will require transparency, hybrid reporting and thoughtful change management. The payoff is improved predictability, earlier mitigation and more credible executive communication.

Non-linear models are possible. It is time to move beyond the straight line.